Stevenage, United Kingdom

Matthew Campbell


 

Average Co-Inventor Count = 11.2

ph-index = 2

Forward Citations = 9(Granted Patents)


Company Filing History:


Years Active: 2007-2023

Loading Chart...
Loading Chart...
10 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Matthew Campbell

Introduction

Matthew Campbell is a notable inventor based in Stevenage, GB, recognized for his significant contributions to the field of pharmaceuticals. With a total of 10 patents to his name, Campbell has made strides in developing compounds that target various health conditions.

Latest Patents

Among his latest innovations are the Oxepinopyrazole derivatives, which serve as inhibitors of PI3-kinase activity. This invention focuses on compounds of formula (I) and their salts, showcasing their potential in inhibiting kinase activity. Another significant patent is for Benzoimidazole derivatives, which act as PAD4 inhibitors. These compounds, also defined by formula (I), may be beneficial in treating a range of disorders, including rheumatoid arthritis, vasculitis, systemic lupus erythematosus, ulcerative colitis, cancer, cystic fibrosis, asthma, cutaneous lupus erythematosus, and psoriasis.

Career Highlights

Matthew Campbell has worked with prominent companies in the pharmaceutical industry, including Glaxo Group Limited and GlaxoSmithKline Intellectual Property Development Limited. His experience in these organizations has contributed to his expertise in drug development and innovation.

Collaborations

Throughout his career, Campbell has collaborated with notable colleagues such as Christopher Roland Wellaway and Michael David Barker, further enhancing his contributions to the field.

Conclusion

Matthew Campbell's work exemplifies the impact of innovative thinking in the pharmaceutical industry. His patents reflect a commitment to addressing complex health issues through scientific advancements.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…